NT
Navega Therapeutics, Inc.
SEC filingBiotechnology · San Diego, CA
Amount raised$1.3Msold at filing
Total offering$2.5M$1.2M still open
Investors in the raise8count reported to the SEC
FiledJan 30, 2026first sale Jan 2, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Randy SocolExecutive Officer
Fernando AlemanExecutive Officer, Director
Ana MorenoExecutive Officer, Director
Executive officers, directors and promoters as listed on the Form D.